Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 11, 2021
Deals
March 10 Quick Takes: Eddy Wu’s Arctic Vision raises $100M; plus Touchlight, NeoPhore, MediciNova-BARDA and Neurelis
Arctic Vision (Shanghai) Biotechnology Co. Ltd. raised $100 million in a series B round led by Loyal Valley Capital. The funds will go in part to support the company’s trio of late-stage
BioCentury | Jan 30, 2021
Product Development
ALS looks up as clinical pipeline explodes
Three late-stage readouts this year and multiple mechanisms in the clinic could lift the lid on ALS treatments
BioCentury | Dec 2, 2020
Emerging Company Profile
Sofinnova’s Papiernik, Costa and Roche alum Garibaldi carve orphan neurology play Noema out of the pharma’s assets
Emerging Company Profile: Noema emerges from stealth with $59M to develop four clinical neurology programs in-licensed from Roche
BioCentury | Apr 10, 2020
Product Development
COVID-19 roundup: New immune targets to address pandemic; plus updates from CanSino, Arcturus, Fujifilm and more
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
BioCentury | Nov 15, 2019
Product Development
Minerva on the verge in neuropsychiatry with two compounds close to verdict
Minerva nears make-or-break readouts from its two founding neuropsychiatry programs
BioCentury | Jul 12, 2019
Company News
MediciNova gets bounce after revealing clinical plan for MS therapy
BioCentury | May 4, 2018
Clinical News
MediciNova reports additional Phase Ib/IIa data for ibudilast in ALS
BioCentury | May 4, 2018
Clinical News
MediciNova reports additional Phase IIb data for ibudilast in MS
BioCentury | Mar 30, 2018
Clinical News
MediciNova's ibudilast misses in Phase II for methamphetamine dependence
Items per page:
1 - 10 of 56